Introduction: What they say
A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, California, USA; and Koch Institute at MIT, 500 Main Street, Cambridge, USA shows that “Fasting-Mimicking Diet Promotes Ngn3-Driven ß-Cell Regeneration to Reverse Diabetes.” This research paper was published, in the 23 February 2017 issue of the journal “Cell” [One of the best research journals in Biology with an I.F of 28 plus], by Prof. and Director of Longevity institute Valter Longo, Cheng CW and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A glycolipid comes to rescue of blood sugar disease: α-Galactosylceramide-based regenerative therapy for reversing diabetes: α-Galactosylceramide (α-GalCer), a synthetic glycolipid derived from Agelas mauritanius, increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene
From significance of the study to Public health relevance:
Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.
What is known?
It has recently been shown that fasting mimicking diet (FMD):(1) increases the expression of Sox17, Pdx-1 (Pancreatic And Duodenal Homeobox 1), & Ngn3 (Neurogenin-3) sequentially; (2) promotes regeneration of insulin-producing ß cells; (3) decreases PKA (Protein Kinase A) and mTOR activity; (4) increases reprogramming proteins Sox2 and Ngn3 expression; (5) increases insulin secretion; and (6) promotes glucose homeostasis, suggesting that FMD: (i) promotes reprogramming of pancreatic cells to restore insulin secretion in islets; and (ii) can reverse both T1D and T2D.
From research findings to Therapeutic opportunity:
This study suggests, for the first time, an α-Galactosylceramide (α-GalCer)-based regenerative therapy for T1D and TIID. α-Galactosylceramide (α-GalCer) has been shown to decrease blood sugar and protect against autoimmune diabetes. However, the mechanism of action remains elusive.
α-Galactosylceramide (α-GalCer), by increasing the expression of its target genes, its may increase the expression of Sox17, Ngn3, Sox2, Pdx-1, NKX6.1, Pax6, INS etc. (Fig. 1). Thereby, it may: (1) decrease the expression of mTOR; (2) increase generation of insulin-producing ß cells; (3) increase insulin secretion; and (4) promote glucose homeostasis, suggesting that α-Galactosylceramide (α-GalCer)–may replace the need for FMD (Fast mimicking diet) or function as an effective alternative to FMD–may find their use in clinic in attenuating and/or reversing both T1D and T2D, as they turn on most of the reprogramming/insulin-producing genes turned by the FMD (Fig.1).
Thus, α-Galactosylceramide (α-GalCer) or its analogs, either alone or in combination with other compounds, may be used to treat and cure T1D and T2D (Fig.2). Together, this study suggests, for the first time, that agavins-based therapy may be used to treat and/or cure T1D and T2D.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How α-Galactosylceramide (α-GalCer) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3?
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., A glycolipid comes to rescue of blood sugar disease: α-Galactosylceramide-based regenerative therapy for reversing diabetes: α-Galactosylceramide (α-GalCer), a synthetic glycolipid derived from Agelas mauritanius, increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 27/May/2018, 11.34 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at email@example.com